Introducing an important therapy for obesity to primary care: once-weekly subcutaneous semaglutide 2.4 mg
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2149005
Pharmacotherapy is typically recommended as an adjunct to lifestyle intervention to help achieve and maintain weight loss for those with obesity (body mass index [BMI] of ≥30 kg/m 2) or...
Conclusions/Relevance: The availability of once-weekly semaglutide 2.4 mg for weight management, as an adjunct to increased physical activity and a reduced-calorie diet that is individualized, scientifically supported, and relevant to the patient, represents an important advance in therapeutic options for patients with overweight or obesity.
Share
-
Dr Hamid3yrObesity is a complex, chronic disease that represents a global public health challenge
Exploring the wider benefits of semaglutide treatment in obesity: insight from the STEP program
Source : https://www.tandfonline.com/doi/full/10.1080/00325481.2022.2150006
ABSTRACT ABSTRACT Obesity negatively impacts patients' health-related quality of life (QOL) and is associated with a range of complications such as type 2 diabetes (T2D), cardiovascular disease, and sleep apnea,...
Conclusions/Relevance: Taken together, these are important considerations for primary care when incorporating pharmacotherapy for weight management.
Share
Cardiometabolic risk factors efficacy of semaglutide in the STEP program - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36691308/
People with overweight or obesity often suffer from associated cardiometabolic diseases and comorbidities. Current therapies for obesity include lifestyle intervention, bariatric surgery, and pharmacotherapy. The magnitude of weight loss achieved...
Conclusions/Relevance: Overall, across the STEP trials, treatment with semaglutide 2.4 mg versus placebo improved cardiometabolic risk factors associated with obesity, illustrating an effective treatment option for people with overweight (and associated comorbidities) or obesity.
Share
Two-year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5 - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36655300/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: In adults with overweight/obesity, semaglutide 2.4 mg improved short- and longer-term control of eating associated with substantial weight loss.
Share
Semaglutide treatment attenuates vessel remodelling in ApoE−/− mice following vascular injury and blood flow perturbation
Source : https://www.sciencedirect.com/science/article/pii/S2667089522000165?via=ihub
Randomized clinical studies have shown a reduction in cardiovascular outcomes with glucagon-like peptide 1 receptor agonist (GLP-1RA) treatment with t...
Conclusions: Semaglutide treatment reduced vessel remodelling following electrical injury and blood flow perturbation in an atheroprone mouse model. This effect appears to be driven by anti-inflammatory and -proliferative mechanisms independent of GLP-1 receptor-mediated signalling in the resident vascular cells. This mechanism of action may...
Share